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Abstract
Background: Clinical genome and exome sequencing (CGES) is primarily used
to address specific clinical concerns by detecting risk of future disease, clarifying
diagnosis, or directing treatment. Additionally, CGES makes possible the disclo-
sure of autosomal recessive and X‐linked carrier results as additional secondary
findings, and research about the impact of carrier results disclosure in this context
is needed.
Methods: Representatives from 11 projects in the clinical sequencing exploratory
research (CSER) consortium collected data from their projects using a structured
survey. The survey focused on project characteristics, which variants were offered
and/or disclosed to participants as carrier results, methods for carrier results dis-
closure, and project‐specific outcomes. We recorded quantitative responses and
report descriptive statistics with the aim of describing the variability in approaches
to disclosing carrier results in translational genomics research projects.
Results: The proportion of participants with carrier results was related to the
number of genes included, ranging from 3% (three genes) to 92% (4,600 genes).
Between one and seven results were disclosed to those participants who received
any positive result. Most projects offered participants choices about whether to
receive some or all of the carrier results. There were a range of approaches to
communicate results, and many projects used separate approaches for disclosing
positive and negative results.
Conclusion: Future translational genomics research projects will need to make
decisions regarding whether and how to disclose carrier results. The CSER con-
sortium experience identifies approaches that balance potential participant interest
while limiting impact on project resources.
KEYWORD S
carrier testing, exome, genome, secondary findings, translational genomics research
1 | INTRODUCTION
Clinical genome and exome sequencing (CGES) is primar-
ily used to address specific clinical concerns by detecting
risk of future disease, clarifying diagnosis, or directing
treatment (Biesecker & Green, 2014). The American Col-
lege of Medical Genetics and Genomics (ACMG) currently
recommends offering secondary results for 59 genes for
which medical actions that can ameliorate or prevent harm
are available (Kalia et al., 2017). Despite the clinical avail-
ability of CGES, there remains a need for translational
research to better understand the benefits and limitations
that can guide clinical use and policy. In addition, CGES
makes possible the disclosure of autosomal recessive and
X‐linked carrier results as additional secondary findings,
and research about the impact of carrier results disclosure
in CGES is complicated and timely. None of the secondary
results recommended by the ACMG are carrier results for
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autosomal recessive disorders (Green et al., 2013; Kalia et
al., 2017). Carrier testing may be perceived as valuable for
those seeking to assess risks for a current or future preg-
nancy (Edwards et al., 2015), but when carrier results are
offered as a secondary finding in CGES, the level of inter-
est and impact may vary widely.
The disclosure of carrier status as part of CGES is
complicated because offering results for hundreds of con-
ditions is in stark contrast to the standard of focused car-
rier testing over the last 40 years. Carrier testing has
expanded slowly since the 1970s with only a handful of
conditions recommended by professional guidelines from
the American College of Obstetrics and Gynecology
(ACOG) and the ACMG (ACOG Committee on Genetics
2004; American College of Obstetricians and Gynecolo-
gists Committee on Genetics 2011; Kalia et al., 2017).
Gradual expansion has occurred following health services
research suggesting that benefits to carrier testing exist
and the risks are modest (Grody, 2016). Yet even for the
widely available cystic fibrosis carrier testing, it is not
clear how often testing is offered to patients and how
often tests are performed (Ioannou et al., 2014). Numer-
ous factors may have contributed to the relatively slow
expansion. One is the belief that only serious disorders
should be included, complicated by lack of consensus on
the threshold for seriousness (Wertz & Knoppers, 2002).
Furthermore, there is a concern that carrier testing and
prenatal screening could devalue the lives of those with
disabilities by allowing a single feature to represent the
entire individual (Parens & Asch, 1999; Parens & Asch,
2000). Finally, some worry that such information may
create difficult decisions for patients or family members
(Press, Wilfond, Murray, & Burke, 2011).
These concerns, still unresolved, have new urgency as
technologies make it possible to examine carrier status for
thousands of genes. Currently available commercial panels
can detect variants for hundreds of rare conditions (Lazarin
et al., 2013; Nazareth, Lazarin, & Goldberg, 2015). Yet it is
not clear if the identification and disclosure of carrier status
is an appropriate use of CGES technology, which has the
potential to provide information on nearly any condition
with recessive or X‐linked inheritance. There is currently no
consensus regarding how to approach carrier testing and
results disclosure from CGES. There are limited data on the
risks and benefits of expanded carrier results disclosure and
limited translational genomics research that evaluates carrier
screening using CGES (Kauffman et al., 2017).
The clinical sequencing exploratory research (CSER)
consortium, funded by NHGRI and NCI from 2011 to
2017, was made up of 18 extramural research projects and
one NHGRI intramural project (Green et al., 2016). The
goals of these projects were to understand the clinical
implications of CGES and create an evidence base to
support appropriate clinical integration of this emerging
technology. Many CSER translational research projects dis-
closed carrier results as a secondary result. Several projects
have published outcomes that include carrier testing (Bie-
secker et al., 2018; Cirino et al., 2017; Lewis et al., 2018;
Parsons et al., 2016; Vassy et al., 2017; Wynn et al.,
2017). The Consortium's Actionability/Return of Results
Working Group sought to understand the variability in
CSER approaches to identifying and disclosing carrier
results, including (1) selection of genes and variants; (2)
choices given to research participants regarding which
results to disclose; (3) results communication approaches;
and (4) project outcomes, including the proportion of indi-
viduals with carrier results and which genetic variants are
commonly identified. The broad range of experiences
across CSER projects allowed us to distill key considera-
tions important for guiding future translational genomics
research projects that will inform decisions regarding
whether and how to disclose carrier results. This research
may in turn help to guide policy decisions about clinical
services.
2 | MATERIALS AND METHODS
A CSER working group requested that the 19 CSER
research projects, including U‐award projects, R‐award pro-
jects, and the NIH project, indicate which projects offer
and/or disclose carrier results. The U‐award projects and
the NIH project assessed sequencing results in the health-
care setting. Eight of the nine U‐award projects and the
NIH project disclosed carrier results. The R‐award projects
were heterogeneous in design regarding research results.
Only three R‐award projects disclosed any results, and two
included carrier results. Thus, 13 projects were identified
as disclosing results, 11 of which included carrier results.
In order to ensure that the questions were relevant for each
project, we developed a survey in collaboration with repre-
sentatives from each of these 11 projects.
The quantitative, descriptive survey gathered informa-
tion on: project characteristics, how many carrier status
genes/conditions were screened for, which pathogenicity
categories were disclosed for carrier results and other sec-
ondary findings (findings unrelated to the primary indica-
tion for the test), how results were disclosed and by whom,
and project‐specific outcomes regarding the number of par-
ticipants, which genes (for carrier variants) were identified,
and whether the participants chose to receive carrier results.
Once finalized, the survey was distributed to each project's
principal investigator or designee. We conducted a phone
interview for the representative and interviewer (KMP) to
review the survey questions. Responses were entered elec-
tronically by the interviewer using REDCap.
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Initial data collection took place between March and
August 2015. Follow‐up correspondence and conversations
took place through February 2016. A final follow‐up con-
versation occurred between May and August 2016 to
gather updated data (current for each site as of May 1,
2016). We utilized descriptive statistics because the survey
was administered to only 11 projects.
3 | RESULTS
3.1 | Study characteristics and background
Of the 11 project teams that completed the survey, two per-
formed genome sequencing only, eight performed exome
sequencing only, and one performed both. The mix of adult
and child participants varied across the projects and
included those that focused exclusively on the pediatric
population, those with a mix of pediatric and adult partici-
pants, and those primarily serving adults. Specific clinical
problems targeted by the projects included cardiovascular
diseases (n = 6), cancer (n = 5), and birth defects and
developmental delay (n = 4). Three projects recruited a
healthy/general population and one focused on preconcep-
tion carrier screening. More detailed information about the
research projects has been previously published in an over-
view of the CSER consortium (Green et al., 2016).
3.2 | Selection of genes/conditions to disclose
for carrier status
As illustrated in Table 1, projects disclosed carrier results
for as few as three and as many as 4600 autosomal reces-
sive or X‐linked genes. Six projects developed a gene list
prior to sequencing and disclosed only carrier status vari-
ants in the genes on the list. In contrast, four projects uti-
lized a postsequencing review process, deciding after
analysis of each participant's exome/genome whether to
disclose the observed variants based on evidence review of
the relevant genes and variants. One project utilized both
methods, automatically disclosing carrier results for three
genes but deciding after analysis whether to disclose other
gene variants.
Figure 1 illustrates the variant pathogenicity classes dis-
closed by each project. All projects disclosed carrier results
for previously reported variants with sufficient evidence to
be classified as pathogenic, while nine disclosed carrier
results for novel variants that were classified as pathogenic.
Six projects disclosed carrier results for likely pathogenic
variants (both previously reported and novel). Only two
projects disclosed carrier results for variants of uncertain
significance (VUS) (both previously reported and novel).
One of these two projects reported only a subset of VUS,
those variants that favor pathogenic, which accounted for
<1% of the VUS results they saw. For comparison, projects
treated the disclosure of other secondary findings (e.g.,
variants in potentially actionable autosomal dominant
genes) similarly, the one exception being that three projects
disclosed VUS (both previously reported and novel) for
these other secondary findings.
3.3 | Participant choices
Nine projects allowed participants to choose whether or not
to receive some or all of the available carrier results, while
the remaining two required disclosure as part of the study
design. Of the projects disclosing carrier results optionally
(i.e., offering), all but one reported between 85%–100% of
participants being willing to receive some or all carrier
results, while the remaining project reported only 27%
uptake. This latter project used a study design in which the
primary diagnostic results and medically actionable sec-
ondary results were disclosed first. Participants were then
asked to make decisions about other categories of results
TABLE 1 Number of genes or conditions and timing of review
for carrier status disclosure among CSER projects
Project Presequencing Postsequencing
Dana‐Farber Cancer
Institute
3 (genes)
HudsonAlphaa 3 (genes) OMIM recessive disorders
(conditions)
University of
Washington
10 (genes)
Seattle Children's
Hospital
29 (genes)
Kaiser Permanente
Northwest
668 (genes)
Children's Hospital
of Philadelphia
186 (genes)
Columbia University OMIM recessive
disorders (conditions)
University of North
Carolina,
Chapel Hill
OMIM recessive
disorders (conditions)
Baylor College
of Medicine
OMIM recessive
disorders (conditions)
National Human
Genome
Research Institute
1508 (genes)
Brigham and
Women's Hospital
4600 (genes)
aAlways offers to disclose carrier status for three genes (CFTR, HBB, HEXA),
but also performs trio sequencing so will offer to disclose carrier status for
disease‐linked genes in OMIM when both mother and father are carriers.
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(e.g., carrier status, pharmacogenomics, APOE status).
Those who desired the further results were asked to call to
request this analysis. Notably, among those who chose to
learn any of their additional results in this project, 88%
opted for carrier results, suggesting that the lower observed
uptake was likely not specific to carrier status but rather a
lower uptake of additional genomic results in general.
3.4 | Results communication
Six projects always communicated positive carrier results
in person (four by a genetic professional, one by a non-
genetic professional, and one by both). Four projects some-
times communicated positive results in person (two by a
genetic professional, two by both), using a phone call as
the alternative to an in‐person meeting. Two projects also
used some other electronic method (i.e., website) as an
alternative. Some projects (n = 3) provided a letter/email
as a follow‐up or in addition to an in‐person discussion.
One project disclosed carrier results to physicians rather
than directly to participants.
Only six of the eleven projects communicated negative
carrier results. Three of these always communicated the
negative carrier results during the course of an in‐person
meeting (one by a genetic professional, one by a non-
genetic professional, and one by both). This could be due
to study design rather than an explicit decision to present
negative results in this format (e.g., an in‐person meeting
was already taking place and therefore was a logical time
to disclose negative results). One of the six projects some-
times disclosed negative carrier results in person, using a
phone call as the alternative. The final two projects never
disclosed negative carrier results in person and instead sent
a letter/email to inform the participant. Some of the pro-
jects that conveyed negative results in person also provided
the participant with a letter or other document that summa-
rized the findings.
3.5 | Outcomes
The number of participants in each CSER project that com-
pleted sequencing and had carrier results analyzed ranged
from 19 to 640. The percentage of participants who
received at least one carrier result ranged from 3% to 92%
per project, with variation primarily due to differences in
the number of genes for which variants were reviewed (see
Figure 2). Between one and seven results were disclosed to
those participants who received any positive result.
Table 2 shows the genes in which variants were most
frequently disclosed in each project. Variants in these genes
cause some of the most common recessive disorders in the
U.S. population (Adam et al., 2016).
3.6 | Carrier results as the primary finding
In contrast to the other 10 projects for which carrier results
were secondary findings, carrier results were the primary
finding for one project that was focused on preconception
carrier screening. This project performed genome sequenc-
ing and included only adult participants who were inter-
ested in preconception carrier screening. The study
disclosed results for 668 genes (corresponding to 728 gene‐
condition pairs) and utilized a presequencing review pro-
cess, developing a gene list prior to sequencing and
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FIGURE 1 Disclosure of pathogenicity variant categories for carrier and secondary findings in CSER projects
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disclosing only carrier status variants in the genes on the
list. This project disclosed carrier results for both previ-
ously reported and novel variants with sufficient evidence
to be classified as pathogenic or likely pathogenic. Due to
the goals of the study, carrier result reporting was required
for all participants. Positive results were always communi-
cated in person by a genetic professional while negative
results were reported via letter/email. As of May 1, 2016,
135 participants completed sequencing and had carrier
results analyzed. 75% of these participants received at least
one carrier result.
4 | DISCUSSION
CSER project approaches to disclosing carrier results var-
ied, including whether carrier results were the primary or
secondary finding, the number of genes reviewed, the vari-
ant categories of pathogenicity that projects disclosed, and
the results communication approach. While this descriptive
study does not provide sufficient evidence to determine the
best approach to disclosing secondary carrier results from
CGES, we identify some specific issues that translational
genomics research projects face and ways in which CSER
3% 5%
26%
44%
75% 77%
85% 85%
88%
92% 92%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
FIGURE 2 Participants with at least one positive carrier result disclosed in CSER projects. This figure includes the total number of
conditions reviewed by each project as indicated in Table 1.
TABLE 2 Most commonly disclosed genes for carrier status per CSER projecta
Gene (condition)
Number of projects that
list gene among the three
most commonly disclosed
Number of projects
that would disclose Disease prevalence
HFE (HFE‐associated hereditary
hemochromatosis)
5 7 1/200–1/400
GJB2 (nonsyndromic hearing loss) 5 9 1/7,000
CFTR (cystic fibrosis) 4 11 1/3,200 (Northern European Ancestry)
BTD (biotinidase deficiency) 4 8 1/60,000
SERPINA1 (alpha‐1 antitrypsin deficiency) 4 8 1/50,00–1/7,000
HBB (sickle cell disease) 2 11 1/300–1/500 (African American Ancestry)
aGenes reported by only one of the 11 CSER projects as most frequently disclosed include HEXA, ABCA4, CYP21A2, MUTYH, LRTOMT, F11, IDUA, ACADM,
CD36, DUOX2, OTOF, ABCC6, C2, SACS, and SMPD1.
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projects approached them. For example, several projects
returned carrier results for HFE‐associated hereditary
hemochromatosis but it was not within the scope of this
survey to determine why that decision was made by each
individual project. While these results would not typically
be disclosed in the clinical setting, research projects have
greater flexibility related to their scientific goals (Jarvik et
al., 2014).
Most participants in these translational genomics
research projects were willing to receive their carrier
results. Ascertainment of carrier status in an adult has the
ability to inform reproductive decision‐making, facilitate
early diagnosis and treatment for their child with a genetic
condition, and alert other family members to their risk sta-
tus (Grody et al., 2013; Himes et al., 2017 Jul; Schneider
et al., 2016). Participants may value this information for
reasons including, but not limited to, increasing sense of
control, lessening anxiety, helping with decision‐making,
and preparing for the possibility of a child with the condi-
tion (Schneider et al., 2016). However, some participants
may not want this information if they are not of reproduc-
tive age or if the information is not likely to change repro-
ductive decisions or might produce stress (Schneider et al.,
2016). Because reproductive decisions involve personal
values, individuals will vary in their attitudes toward, and
use of, carrier status information, but some participants
endorse the value of choice, including the choice of
whether or not to receive carrier status results (Schneider et
al., 2016).
More translational genomics research is needed on the
implementation of CGES for ascertainment of carrier sta-
tus. As the CSER projects illustrate, although some projects
focus primarily on carrier results, most CGES projects face
the question of whether to include carrier results among the
secondary findings they offer to disclose. As commentators
have suggested, translational research projects do not have
a compelling obligation to disclose carrier results, and
instead may decide whether or not to offer such results to
participants (Fabsitz et al., 2010; Jarvik et al., 2014; Presi-
dential Commission for the Study of Bioethical Issues
2013; Wolf et al., 2012). However, given the high percent-
age of CSER participants who were willing to receive car-
rier results, future translational genomics researchers should
consider the possibility, both to study the utility of offering
these results and to respond to participants’ interest (Ravit-
sky & Wilfond, 2006; Richardson & Belsky, 2004). When
carrier results disclosure is not a scientific aim of a
research project, researchers need to balance offering these
results with obligations to steward resources to address
research questions when deciding whether to offer results.
Results disclosure should meet CLIA standards for analytic
validity, and ensure appropriate results interpretation and
communication by adequately trained personnel.
Based on our experience, we identify some approaches
that consider participant interest while bearing in mind the
impact on project resources. First, a project can limit the
number of genes or conditions included for carrier variant
reporting and disclose results based on frequency and seri-
ousness, thereby focusing on the most clinically meaningful
results to provide the greatest value given limits of capacity
(see Figure 2). Second, a project can limit disclosure to a
predetermined list of variants, thereby reducing time spent
on pathogenicity classification and orthogonal validation.
Third, a project can decide to disclose only pathogenic
variants. Fourth, a project can disclose results only when
both partners planning a pregnancy are carriers for variants
in the same gene; this would lead to a dramatic reduction
in the number of positive results disclosed and focus on
information that would impact clinical management (Wald,
George, Wald, & Mackenzie, 1993). Finally, projects can
ask participants about carrier results analysis following tar-
geted deliberation (e.g., using a specific decision aid or
being asked to call, text, or register online to request this
analysis separate from the primary decision to enroll in the
study and receive primary results). The CSER project that
utilized such an approach experienced a much lower per-
centage of participants who ultimately opted to receive car-
rier results, thus limiting the effort spent by the research
team on interpretation, while still providing carrier results
for interested individuals.
4.1 | Limitations
This study has a few limitations. First, the CSER consor-
tium was not designed for direct comparisons of various
approaches across projects. Carrier detection was the pri-
mary goal of the sequencing for only one of the 11 pro-
jects; other projects might have used different approaches
if carrier screening was a primary goal. While including
one study primarily aimed at carrier screening with 10
studies for which carrier results were secondary might bias
our findings because of a specific study population or a
more deliberative process in that study, our findings show
that this one carrier‐focused study did not differ from the
others with respect to interest in carrier screening or per-
centage of participants with positive carrier results. Our
analysis was limited to projects using CGES and did not
include other platforms such as expanded carrier screening
panels using targeted genotyping or sequencing. The high
uptake for carrier status results observed in most projects
may have reflected the distinctive populations of individu-
als who were willing to receive clinical sequencing at this
stage of its development and more diverse populations and
settings might show a different frequency of uptake. Addi-
tionally, we recognize the importance of data about the
impact of carrier results disclosure on participants but
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herein we limit our focus to the variability of approaches
taken by the various CSER projects. Nonetheless, this is
the largest description of approaches to carrier results dis-
closure in translational genomics sequencing research to
date. This description is valuable because multiple projects
are represented with distinct study designs allowing insight
into the breadth of approaches that were used in the CSER
consortium.
4.2 | Considerations for future translational
genomics research
Based on the CSER experience, we are able to provide
insight into research approaches using CGES for carrier
status and provide suggestions for future translational geno-
mics research that evaluates the clinical impact of disclos-
ing carrier results in CGES. Carrier results may be offered
to research participants either because this disclosure
addresses specific research questions or because the
research team is motivated by the potential personal value
of this information to participants to justify disclosure as
secondary results. The following considerations are focused
on disclosure of these secondary results because of poten-
tial value to participants and not related to addressing
specific research questions, which may direct the specific
approach. Each consideration leads to specific questions
that would need to be answered by future projects, as seen
in Table 3. These considerations are based in part on the
findings from this study but also on our experiences as
researchers in the field.
4.2.1 | Selection of genes/conditions to offer
for carrier status
Translational genomics research projects should decide
whether to offer participants the choice to receive carrier
results as a secondary finding from CGES (Darnell et al.,
2016). Carrier results for autosomal recessive disorders
have thus far not been included on the ACMG list of
actionable results that are recommended to be offered to
patients in clinical sequencing (Green et al., 2013; Kalia et
al., 2017), but in the context of research, investigators may
decide to offer carrier results to respond to participants’
interest in these results or to create an evidence base to
inform this practice (Jarvik et al., 2014). Research teams
should exercise discretion when deciding to offer carrier
results and only do this if they have capabilities to provide
appropriate handling, interpretation, and communication
(Grody, 2016). We are not suggesting that carrier results
must be routinely offered as part of CGES research as con-
sensus has not been reached.
Ideally, studies would use specific, predetermined crite-
ria to decide which variants/genes/conditions to disclose.
Given the lack of consensus on such criteria or thresholds
(Himes et al., 2017; Wilfond & Goddard, 2015), each pro-
ject should have a deliberative process for developing and
applying those criteria. We suggest that projects consider
the well‐established association of the gene and variant
with a condition as a primary criterion.
Two additional criteria to be considered are the fre-
quency and seriousness of the condition. We acknowledge
that frequency and seriousness exist on a continuum, and it
is not clear what threshold should be used. An even more
challenging caveat is that seriousness, unlike frequency,
has a subjective dimension (Wertz & Knoppers, 2002).
Seriousness appears to be related to motivations for receiv-
ing carrier results, although different individuals will have
varying views about what should be considered serious
(Schneider et al., 2016). Seriousness can be defined in a
range of ways, including categorical features such as
TABLE 3 Four challenges to address in considering the use of
CGES to ascertain and disclose carrier results in translational
genomics research
General challenges Specific questions
Whether or not to offer to
disclose carrier results
What is the likely perceived utility
of carrier results in this study
population?
Can the research team inform their
decisions on whether and how to
offer carrier status findings
through pilot studies or other
research on participant interest in
these findings and the feasibility
of disclosure?
Selection of genes/
conditions to disclose
for carrier status
What specific criteria will be used?
Will the genes/conditions selected for
disclosure be determined before or
after sequencing takes place?
Will novel variants be disclosed?
What levels of pathogenicity
will be disclosed?
Participant choices Can participants choose whether or
not to receive results?
Can participants choose specific
categories of results?
Will participants be asked to use a
distinct process to make the decision
of whether to receive carrier results?
Results disclosure
process
Will results be disclosed via in person
meeting, phone, email/letter,
or internet?
Who will convey the results?
Will both positive and negative
results be disclosed?
Will positive and negative results be
conveyed in the same way and/or
by the same type of provider?
8 | PORTER ET AL.
effects on life span, cognitive functioning, health system
interactions, intensity of symptoms, variability of presenta-
tion, and age of onset (Korngiebel et al., 2016). Individu-
als’ interpretation of these features may be influenced by
personal experience, and families and researchers may view
them differently. More research is needed to use the “seri-
ousness” criterion optimally. For instance, in one CSER
project, an aspect of “seriousness” that was considered
important was whether a condition was “medically
involved” (Korngiebel et al., 2016), meaning that the con-
dition involved occasional or regular medical evaluations
and monitoring and/or home medical interventions, such as
may occur in more familiar pediatric conditions like asthma
or diabetes as well as many autosomal recessive disorders.
For some families, focusing on “medical involvement” may
decrease interest in testing if a chronic pediatric disease is
perceived as something that can be managed and accepted.
Likewise, interest might increase if pediatric chronic illness
is perceived by families as something to be avoided.
Acknowledging the lack of consensus in the field as to
whether carrier results should be disclosed as secondary
findings in research projects using CGES (Green et al.,
2012; Yu, Harrell, Jamal, Tabor, & Bamshad, 2014), all
the CSER projects that disclosed carrier results included
known variants that are classified as pathogenic based on
ACMG criteria (Richards et al., 2008). Among the CSER
projects, VUSs were not disclosed unless researchers had a
question specifically addressing the impact of disclosing
VUSs. However, there was variability regarding whether
projects disclosed likely pathogenic variants as secondary
findings. Notably, the ACMG criteria themselves have been
interpreted in divergent ways and the same variant can be
classified differently by different laboratories (Amendola et
al., 2016).
4.2.2 | Participant choices
When projects decide to offer carrier testing results, indi-
viduals should be able to choose whether or not to receive
carrier results. If disclosure of carrier status is an integral
part of the study design and participant choice is not an
option, that should be clearly conveyed to participants so
they can choose whether or not to enroll in the study
(Burke, Trinidad, & Clayton, 2013). Carrier status may be
important information for some but unwanted information
for others, as the value of the information is based on per-
sonal choices for reproductive decision‐making, planning
for health of the family, and life stage. There is not yet evi-
dence to conclude that offering different categories of car-
rier results to select from (e.g., lifespan‐limiting, serious,
adult‐onset, unpredictable) is feasible or necessary (Korn-
giebel et al., 2016), although further research could guide
such approaches in the future.
Researchers contemplating carrier results disclosure will
need to consider how to structure participant decision‐mak-
ing, including when to ask participants to decide if they are
interested in receiving carrier results. One CSER project
asked participants to decide about carrier results analysis at
a separate time, subsequent to the disclosure of primary
findings. Further research is needed on how best to struc-
ture participant decision‐making about carrier status. Indi-
viduals will differ in how much value they place on carrier
results. Other studies have shown that uptake of carrier
screening is lower, for example, when invitations are sent
by mail, thereby requiring action on the part of the patient,
compared to routinely offering carrier testing results during
a primary care visit (Bekker et al., 1993; Henneman et al.,
2016). In addition to the example of a second request for
analysis, other options could include asking participants to
use a decision‐aid to determine their interest in receiving
carrier status results; some decision‐aids have been used to
improve understanding and promote value‐based decision‐
making related to genetic testing in other contexts (Birch et
al., 2016). Such approaches may not be feasible in all stud-
ies, but targeted approaches may allow for disclosure to the
subset of participants most interested in these results.
4.2.3 | Results disclosure process
Positive results have been disclosed in person, by phone,
letter, or online. There are limited data to guide these pro-
cesses and future studies should collect data about a range
of relevant participant and family outcomes, such as under-
standing, decisional regret, health behaviors, and satisfac-
tion, in order to guide future protocols. Ensuring there is
an avenue to address participant questions is vital. Negative
results should be disclosed, especially if patients were
asked to make an “opt in” decision for carrier status
results. Providing negative results can improve understand-
ing by emphasizing the limitations of the negative results.
Adequate communication of negative results requires an
appreciation that interpretations may change over time, that
not all autosomal recessive diseases will be assessed and
that there are other causes of childhood medical conditions
and birth defects.
5 | CONCLUSION
These data show that disclosing carrier results in CGES
research has been undertaken and a number of challenges
associated with this activity exist. Further translational
genomics research on CGES is necessary to guide policy
development about carrier results. Such studies will need to
determine whether to analyze carrier status results as pri-
mary or secondary findings, how to determine the roster of
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carrier status results to analyze, and how to offer and/or
disclose carrier results to participants. The experience of
the CSER Consortium provides insights for these future
studies. Ideally, data collection from such studies can guide
future policy decisions on the clinical integration of gen-
ome sequencing for carrier status (Wilfond & Goddard,
2015).
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